The CRWE Network to Include Business Directory, Amicus Therapeutics (FOLD) Positive Data of Oral Therapy from Fabry Disease Trial |
Posted: November 17, 2014 |
Crown Equity Holdings Inc. (CRWE) CRWE is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites. One of the primary goals of the CRWE Network is to offer business owners the power of consumer targeting advertisements on a local and national scale. The CRWE Network has reached the 1476th community website in the U.S., associated with 3450 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York as well as across 10 provinces in Canada, The CRWE Network's business model is based on selling advertising to businesses targeting both locally and nationally. Each site has local as well as national news coverage with site specific topics depending on what community the visitor is visiting. The CRWE-PR Business Directory portal ( www.BusinessDirectory.crwe-pr.com ) is the company’s business directory service that is available to all United States and Canada business in the public and private sector. It allows business owners and executives the ability to claim their business listings and provide more detailed information for their potential customers who visit the CRWE Network everyday. CRWE plans to have full national coverage of all U.S and Canada businesses in the future on its CRWE-PR Business Directory, which will be integrated to the CRWE Network. Online video is gaining strength as a source for content marketing. Strategic plans are being developed for CRWE’s division CRWE Tube ( www.crwetube.com ) to improve the potential future growth for the company. CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet. More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com ** Amicus Therapeutics, Inc. (FOLD) Fabry disease is an inherited genetic disorder caused by a defective gene. It is caused by a deficiency of the enzyme alpha galactosidase-A (GALA), which usually works to clear fatty substances called glycosphingolipids from the body. The absence of GALA causes fatty deposits in several organs of the body, in the blood and blood vessel walls. This leads to constriction of blood flow through the vessels. Eventually, the decreased blood flow leads to problems of the skin, kidneys, heart, and nervous system. The genetic defect responsible for Fabry disease is located on the X chromosome. The way it gets passed down through families depends on whether the affected parent is male or female. Affected fathers pass the defective gene to all of their daughters and none of their sons, while affected mothers can pass the defective gene to both their daughters and their sons. Fabry disease affects more males than females: It is estimated that 1 in 40,000 males has Fabry disease, whereas the estimated prevalence in the general population is 1 in 117,000 people. The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. Data from the Fabry Registry indicate that the leading cause of death in patients is from cardiac complications. FOLD reported additional positive data on important secondary endpoints from its second Phase 3 study (Study 012) of the oral small molecule chaperone migalastat HCl for Fabry disease. Study 012 was designed to compare the safety and efficacy of FOLD's migalastat to standard of care enzyme replacement therapies (ERTs) (Fabrazyme(R) and Replagal(R)) in patients with Fabry disease who have amenable mutations. In Study 012, patients who switched from ERT to migalastat showed a statistically significant decrease from baseline to month 18 in left ventricular mass index (LVMi). LVMi is a measure of cardiac hypertrophy, an increase in the size of the heart that has been associated with an increased risk of cardiac events in Fabry patients. FOLD intends to seek approval of migalastat in both the European Union and in the U.S. According to the company, it is on track to hold its pre-submission meeting with European regulators this quarter, and expects to interact with the FDA in early 2015. FOLD is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. FOLD is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. More about Amicus Therapeutics, Inc. (FOLD) at www.amicustherapeutics.com ** Disclaimer: This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
|
||||||||||||||||||||||||||||||||||||||||||
|